ribociclib
novartis
['maintain trial', 'bcsm', 'mbc', 'ribociclib']
maintain trial: first prospective results on cdk4/6i beyond progression. favorable impact of #ribociclib after previous exposure to cdk4/6i, still a significant proportion of patients experience early progression, underlining how complex endocrine resistance is #mbc #bcsm #asco22 
Physician scientist, Breast Oncology @CroAviano, @Uniud, @LiquidBioTeam, @CtcLaboratory. #TranslationalResearch, #PrecisionMedicine, Mac Geek, Ramen Addicted.